|
Successfully
Including Women in Clinical Trials
A Guide for Researchers
PDF version
Why
include women in a clinical trial?
Federal regulation and NIH policy require that women, including women
of childbearing potential, be included in all NIH-supported biomedical
and behavioral research involving human subjects unless there is a
clear and compelling rationale that inclusion would harm the subjects
or the purpose of the research.
Research has provided evidence of sex differences in many biological
systems of the body. A womans menstrual cycle can also significantly
change the effect of drugs a woman takes. In addition to sex differences
in biological systems, there are cultural expectations for both men
and women which have an effect on behavior, sense of self, and relationships.
While these differences may make the design of a research study a
greater challenge, the findings also have strong implications for
the way that women should be treated. Simply put, research findings
on men cannot be presumed to have any significance for women.
Why conduct gender analysis?
Including women is just the first step. Conducting a gender analysis
of your data is the next. If sex differences in the way a treatment
works are identified in early phases of research, then subsequent
studies can be designed so that researchers can determine how the
treatment should be used to benefit both men and women. In fact, any
proposal submitted to NIH for a Phase III clinical trial must review
the evidence to show whether or not clinically important sex/gender
differences in the intervention effect are expected.
Federal regulation and NIH policy
require that women, including women of childbearing potential, be
included in all NIH- supported biomedical and behavioral research
involving human subjects unless there is a clear and compelling rationale
that inclusion would harm the subjects or the purpose of the research.
Through gender analysis, we know that:
-
After consuming the same amount of alcohol, women have a higher
blood alcohol content than men, even allowing for size differences,
women metabolize alcohol differently.
Meeting the Challenge
Researchers have traditionally avoided including women in clinical
trials. In addition to concerns about the effect of gender differences
and hormonal fluctuations during the menstrual cycle on study outcomes,
they are worried about possible fetal exposure to drugs and difficulties
recruiting women. However, these challenges are far outweighed by
the importance of including women in our research and they are not
insurmountable.
Three Ways to Minimize the Risk of Fetal Exposure in a Clinical
Trial
-
When recruiting women for your study, remember that many women
of childbearing age are unlikely to get pregnant for instance,
women using a reliable method of contraception, women whose partners
have had vasectomies, and women who are not sexually active.
-
Include all available information regarding the potential risk
of fetal toxicity and potential effects on fertility in the informed
consent document and investigators brochure. If no relevant
information is available, the informed consent should explicitly
note the potential for fetal risk.
-
Reduce the risk of fetal exposure through study design. By administering
treatment during or immediately following a womans menstrual
period or after a pregnancy test or by counseling women in trials
about the need to use reliable forms of contraception, the risk
to fetuses can be avoided.Reducing the risk of fetal exposure
Between 1977 and 1993, the FDA prohibited the inclusion of women
of childbearing age in the early phases of research studies that tested
new medications unless the woman had a life-threatening disease. However,
recent laws and court decisions suggest that women should have the
right to make their own risk-benefit choices about their pregnancies
and are entitled to know all the risks.
Insofar as there will always be a number of women who become exposed
to a medication while pregnant, it is important to know if a medication
affects fetuses or affects pregnant women differently. This can better
be determined by testing the medication in a small number of pregnant
women, than for medications to be used by many women during pregnancy
without reliable information on their maternal and fetal effects.
Improving recruitment and retention of women
Researchers cite many reasons why recruitment of women fails, including
patient noncompliance, lack of incentive to seek alternative therapies,
poor access to health care, lack of transportation, lack of child
care, and mistrust of medical systems. However, NIH requires that
all funded studies include an outreach plan for recruiting women as
participants.
Strategies for Recruiting and Retaining Women in a Clinical Trial
-
Network with emergency rooms, state and county assistance offices,
primary care givers, and mental health centers.
Staff Your Team Right
Often women investigators and educators can foster greater trust
among female participants.
Involve the Patients
-
Create a participant advisory board to give feedback on forms
used, recruitment activities, study procedures, etc.
Improve Communication
-
Inform participants about the study protocol, treatment, trial
outcomes, and implications through meetings, newsletters, or other
updates.
For more information on the National Drug Abuse Treatment Clinical
Trials Network, visit the NIDA website at www.drugabuse.gov
For information on other clinical trials, the National Institutes
of Health (NIH) has created a website to help patients, family members,
and the general public obtain information about government sponsored
clinical trials. You may log on to www.Clinicaltrials.gov
to learn about ongoing or new trials for all types of health related
conditions.
|
![](/peth04/20041021085404im_/http://drugabuse.gov/CTN/images/shim.gif) |